WG
PHAS

Winton Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Winton Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,990
Closed -$50K – 1830
2019
Q3 		$50K Buy
+11,990
New +$95.6K ﹤0.01% 1499

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Winton Group's PHAS Position: Q4 2019 in Review

Winton Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2019, closing a stake of 11,990 shares — an estimated $50K sold.

Winton Group first reported a position in PHAS in Q3 2019 and held it in 1 quarter. The position peaked at $50K in Q3 2019. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2019.

  • Winton Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Winton Group sold 11,990 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $50K.
  • Winton Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Winton Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $50K in Q3 2019.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.